UniProt Q9UDY8
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (Q9UDY8)
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (UniProt Q9UDY8), EC 3.4.22.-: 38 experimental structures on GenesisL1, 11 ligands bound, 56 pockets. Binding sites, pockets, druggability and 3D structures in…
- UniProt
- Q9UDY8
- Protein
- Mucosa-associated lymphoid tissue lymphoma translocation protein 1
- EC
- 3.4.22.-
- Experimental structures
- 38
- Predicted models
- 0
- Ligands
- 11
- Pockets
- 56 · 6 records with a druggable one
Structures
38 records of Q9UDY8 in the MolNFT archive: 38 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 2G7R | X-ray structure of the death domain of the human mucosa associated lymphoid tissue lymphoma… | x-ray diffraction | A, B | — | — |
| 2G7R | X-ray structure of the death domain of the human mucosa associated lymphoid tissue lymphoma… | x-ray diffraction | A, B | — | — |
| 3BFO | Crystal structure of Ig-like C2-type 2 domain of the human Mucosa-associated lymphoid tissue… | x-ray diffraction | A, B, C, D | — | — |
| 3BFO | Crystal structure of ig-like C2-type 2 domain of the human mucosa-associated lymphoid tissue… | x-ray diffraction | A, B, C, D | — | — |
| 3K0W | Crystal structure of the tandem ig-like C2-type 2 domains of the human mucosa-associated lymphoid… | x-ray diffraction | — | — | |
| 3UO8 | Crystal structure of the MALT1 paracaspase (P1 form) | x-ray diffraction | B, C | — | — |
| 3UO8 | Crystal structure of the MALT1 paracaspase (P1 form) | x-ray diffraction | B, C | — | — |
| 3UOA | Crystal structure of the MALT1 paracaspase (P21 form) | x-ray diffraction | B, C | — | — |
| 3UOA | Crystal structure of the MALT1 paracaspase (P21 form) | x-ray diffraction | B, C | — | — |
| 3V4O | Human MALT1 (caspase domain) in complex with an irreversible peptidic inhibitor | x-ray diffraction | A | — | — |
| 3V4O | Human MALT1 (caspase domain) in complex with an irreversible peptidic inhibitor | x-ray diffraction | A | — | — |
| 3V55 | Human MALT1 (334-719) in its ligand free form | x-ray diffraction | A | — | — |
| 3V55 | Human MALT1 (334-719) in its ligand free form | x-ray diffraction | A | — | — |
| 4I1P | Human MALT1 (caspase-IG3) in complex with activity based-probe | x-ray diffraction | A, C | — | — |
| 4I1P | Human MALT1 (caspase-IG3) in complex with activity based-probe | x-ray diffraction | A, C | — | — |
| 4I1R | Human MALT1 (caspase-IG3) in complex with thioridazine | x-ray diffraction | A | — | — |
| 4I1R | Human MALT1 (caspase-IG3) in complex with thioridazine | x-ray diffraction | A | — | — |
| 6F7I | Human MALT1(329-728) in complex with mlt-747 | x-ray diffraction | A, B | CW5, MG | — |
| 6GK2 | Helical reconstruction of BCL10 CARD and MALT1 DEATH DOMAIN complex | electron microscopy | F | — | — |
| 6GK2 | Helical reconstruction of BCL10 card and MALT1 death domain complex | electron microscopy | F | — | — |
| 6H4A | Human MALT1(329-728) in complex with mlt-748 | x-ray diffraction | A | FNB | — |
| 6YN8 | Human MALT1(334-719) in complex with a tetrazole containing compound | x-ray diffraction | A | OZK | 4 (best 0.69) |
| 6YN8 | Human MALT1(334-719) in complex with a tetrazole containing compound | x-ray diffraction | A | OZK | — |
| 6YN9 | MALT1(329-728) in complex with a sulfonamide containing compound | x-ray diffraction | A | OZQ | — |
| 7A41 | MALT1 in complex with a NVS-MALT1 chemical probe | x-ray diffraction | A, B | QYQ | 11 (best 0.72) |
| 7A41 | MALT1 in complex with a nvs-MALT1 chemical probe | x-ray diffraction | A, B | QYQ | — |
| 7AK0 | Human MALT1(329-729) in complex with a chromane urea containing inhibitor | x-ray diffraction | A, B | RJK | 8 (best 0.74) |
| 7AK0 | Human MALT1(329-729) in complex with a chromane urea containing inhibitor | x-ray diffraction | A, B | RJK | — |
| 7AK1 | Human MALT1(329-729) in complex with a chromane urea containing inhibitor | x-ray diffraction | A | RJH, MG | 3 (best 0.71) |
| 7AK1 | Human MALT1(329-729) in complex with a chromane urea containing inhibitor | x-ray diffraction | A | RJH, MG | — |
| 7PAV | MALT1 in complex with compound 1 | x-ray diffraction | A, B | 6IO | 9 (best 0.84) |
| 7PAV | MALT1 in complex with compound 1 | x-ray diffraction | A, B | 6IO | — |
| 7PAW | MALT1 in complex with compound 1 | x-ray diffraction | A, B | 6IT | — |
| 8CZO | Cryo-EM structure of BCL10 CARD - MALT1 DD filament | electron microscopy | a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p, q, r, s, t, u, v | — | — |
| 8CZO | Cryo-EM structure of BCL10 card - MALT1 dd filament | electron microscopy | a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p, q, r, s, t, u, v | — | — |
| 8J5I | MALT1 death domain | x-ray diffraction | B | — | 1 (best 0.34) |
| 8V4X | Structure of MALT1 in complex with an allosteric inhibitor | x-ray diffraction | A, B, C, D, E, F | A1AAB | 20 (best 0.83) |
| Q9UDY8 | AlphaFold monomer V2.0 prediction for mucosa-associated lymphoid tissue lymphoma translocation… | — | — | — |
Ligands
- MG · Magnesium ion · in 3 records
- 6IO · ~{N}1,~{N}4-bis[2-(trifluoromethyl)pyrimidin-4-yl]cyclohexane-1,4-diamine · in 2 records
- OZK · 3-azanyl-3-methyl-~{N}-[(3~{R})-4-oxidanylidene-5-[[4-[2-(1~{H}-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]-2,3-dihydro-1,5-benzoxazepin-3-yl]butanamide · in 2 records
- QYQ · ~{N}-[(1~{S})-1-[4-[[2-chloranyl-7-[(1~{S})-1-methoxyethyl]pyrazolo[1,5-a]pyrimidin-6-yl]amino]phenyl]-2,2,2-tris(fluoranyl)ethyl]-~{N}-methyl-1,1-bis(oxidanylidene)thiane-4-carboxamide · in 2 records
- RJH · 1-(3-chloranyl-4-methoxy-phenyl)-3-[7-[(3~{S})-3-(methoxymethyl)morpholin-4-yl]-2-methyl-pyrazolo[1,5-a]pyrimidin-6-yl]urea · in 2 records
- RJK · 1-[4-[4-(aminomethyl)pyrazol-1-yl]-3-chloranyl-phenyl]-3-[(3~{R})-6-bromanyl-3,4-dihydro-2~{H}-chromen-3-yl]urea · in 2 records
- 6IT · ~{N}1-(3-chloranyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-~{N}4-[2-(trifluoromethyl)pyrimidin-4-yl]cyclohexane-1,4-diamine · in 1 record
- A1AAB · N-{7-[(1S)-1-methoxyethyl]-2-methyl[1,3]thiazolo[5,4-b]pyridin-6-yl}-N'-[6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl]urea · in 1 record
- CW5 · 1-[2-chloranyl-7-[(1~{S})-1-methoxyethyl]pyrazolo[1,5-a]pyrimidin-6-yl]-3-(5-chloranyl-6-pyrrolidin-1-ylcarbonyl-pyridin-3-yl)urea · in 1 record
- FNB · 1-[2-chloranyl-7-[(1~{R},2~{R})-1,2-dimethoxypropyl]pyrazolo[1,5-a]pyrimidin-6-yl]-3-[5-chloranyl-6-(1,2,3-triazol-2-yl)pyridin-3-yl]urea · in 1 record
- OZQ · 5-[4-[(2,6-diethylphenyl)sulfamoyl]-3-methyl-phenyl]furan-3-carboxylic acid · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.